Wall Street is casting a brighter spotlight on Gossamer Bio (NASDAQ:GOSS) this week after Barclays stepped out with a “Strong Buy” upgrade, a move that suggests a serious shift in sentiment for the clinical-stage biopharmaceutical player.
While the broader analyst community remains a bit more cautious—landing on a “Moderate Buy” consensus with five Buys and a lone Sell—the price targets tell a story of massive potential upside. With an average target sitting at $8.60, analysts are eyeing a significant climb from the stock’s recent opening price of $2.45.
The numbers under the hood, however, remind investors that Gossamer is still very much in the “high-risk, high-reward” phase typical of biotech. The company recently missed earnings expectations slightly, posting a quarterly loss of $0.21 per share against a predicted $0.19 loss.
READ: The XRP Paradox: Why A Massive Legal Win Is Getting Swallowed By A “Red Friday” Flash Crash
With negative margins and a forecast of -$0.28 EPS for the year, the company isn’t profitable yet—but that hasn’t scared off the big players.
Institutional ownership has swelled to over 81%, a remarkably high figure that signals professional money managers are betting on the science rather than the current balance sheet.
Recent filings show a flurry of activity from firms like Legal & General, Ciovacco Capital, and Mirae Asset Global Investments, who have all established or increased their stakes, even if the individual buy-ins remain relatively modest.
At the heart of the excitement is seralutinib, Gossamer’s lead investigational drug.
The company is swinging for the fences in the rare disease space, specifically targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
These are tough, life-altering conditions with limited treatment options, and Gossamer’s pivot toward oral therapies for immune-mediated diseases and oncology (including their GB004 and GB1275 programs) places them in a competitive but lucrative niche.
For a company with a $590 million market cap that saw its stock dip as low as $0.76 in the last year, the Barclays upgrade isn’t just a rating—it’s a signal that the floor might finally be firming up.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
